The Experts below are selected from a list of 15591 Experts worldwide ranked by ideXlab platform
Abed M Zaitoun - One of the best experts on this subject based on the ideXlab platform.
-
predictive value of tumor proliferative indices in periampullary cancers ki 67 Mitotic activity Index mi and volume corrected Mitotic Index m v using tissue microarrays
World Journal of Surgery, 2010Co-Authors: Mark M Aloysius, Shivanthi J De Silva Hewavisenthi, Timothy E Bates, B J Rowlands, Dileep N Lobo, Abed M ZaitounAbstract:Background Morphometry [nuclear Ki-67 labelling, Mitotic activity Index (MI), and volume-corrected Mitotic Index (M/V)] for periampullary cancers using tissue microarrays has not been performed previously. The purpose of the study was to assess these indices on tissue microarray (TMA) sections constructed from patients with periampullary cancers and study their association with clinicopathological variables.
-
predictive value of tumor proliferative indices in periampullary cancers ki 67 Mitotic activity Index mi and volume corrected Mitotic Index m v using tissue microarrays
World Journal of Surgery, 2010Co-Authors: Mark M Aloysius, Shivanthi J De Silva Hewavisenthi, Timothy E Bates, B J Rowlands, Dileep N Lobo, Abed M ZaitounAbstract:Morphometry [nuclear Ki-67 labelling, Mitotic activity Index (MI), and volume-corrected Mitotic Index (M/V)] for periampullary cancers using tissue microarrays has not been performed previously. The purpose of the study was to assess these indices on tissue microarray (TMA) sections constructed from patients with periampullary cancers and study their association with clinicopathological variables. Immunohistochemical staining for Ki-67 was performed on formalin-fixed pancreatic TMA sections. Expression of Ki-67 was assessed as the percentage of cancer cell nuclei expressing MIB1, MI as the mean percentage of Ki-67 from 10 random high-power fields, and M/V was calculated after standardizing MI for connective tissue volume and microscope parameters in the tumor using established protocols. Patients ≥70 years with periampullary cancers had higher Ki-67 expression (>15) compared with patients 15) was clearly associated with worsening histological grade (χ2 = 9.2, P = 0.010). The median survival for tumors of the pancreaticobiliary subtype (pancreatic ductal adenocarcinoma and cholangiocarcinoma) was 43 months in the group with an M/V score of <20, compared with 18 months for the group with a score ≥20 (P = 0.001). There was no statistically significant difference in survival, based on M/V score, for tumors of the intestinal subtype (ampullary and duodenal adenocarcinoma). In periampullary cancers, Ki-67 and MI are proliferative indices predictive of tumor behavior. M/V was predictive of survival in tumors of the pancreaticobiliary subtype.
Adriana Olar - One of the best experts on this subject based on the ideXlab platform.
-
abstract 5270 idh mutation status and role of who grade and Mitotic Index in overall survival in grade ii iii diffuse gliomas
Cancer Research, 2015Co-Authors: Adriana Olar, Khalida Wani, Erik P Sulman, Lindsey Heathcock, Hinke F Van Thuijl, Mark R Gilbert, Terri S Armstrong, Daniel P Cahill, Kristin Diefes, Jaap C ReijneveldAbstract:Diffuse gliomas are up till now graded based upon morphology. Recent findings indicate that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of tumors. The role of tumor grade and Mitotic Index in patient outcome has not been evaluated following stratification by IDH mutation status. To address this, we interrogated 558 WHO grade II-III diffuse gliomas for IDH1/2 mutations and investigated the prognostic impact of WHO grade within IDH-mutant and wild-type tumor subsets independently. The prognostic impact of grade was modest in IDH-mutant [hazard ratio (HR) = 1.21, 95% confidence interval (CI) = 0.91-1.61] compared to IDH-wild type tumors (HR = 1.74, 95% CI = 0.95-3.16). Using a dichotomized Mitotic Index cut-off of 4/1000 tumor cells, we found that while Mitotic Index was significantly associated with outcome in IDH-wild type tumors (log-rank p Citation Format: Adriana Olar, Khalida Wani, Kristin Diefes, Lindsey Heathcock, Hinke van Thuijl, Mark Gilbert, Terri Armstrong, Erik Sulman, Daniel Cahill, Jaap Reijneveld, Bauke Ylstra, Pieter Wesseling, Kenneth Aldape. IDH mutation status and role of WHO grade and Mitotic Index in overall survival in grade II-III diffuse gliomas. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5270. doi:10.1158/1538-7445.AM2015-5270
-
Mitotic Index is an independent predictor of recurrence free survival in meningioma
Brain Pathology, 2015Co-Authors: Adriana Olar, Khalida Wani, Erik P Sulman, Alireza Mansouri, Gelareh Zadeh, Charmaine D Wilson, Franco Demonte, Gregory N Fuller, Kenneth AldapeAbstract:While World Health Organization (WHO) grading of meningioma stratifies patients according to recurrence risk overall, there is substantial within-grade heterogeneity with respect to recurrence-free survival (RFS). Most meningiomas are graded according to Mitotic counts per unit area on hematoxylin and eosin sections, a method potentially confounded by tumor cellularity, as well as potential limitations of accurate Mitotic figure detection on routine histology. To refine Mitotic figure assessment, we evaluated 363 meningiomas with phospho-histone H3 (Ser10) and determined the Mitotic Index (number of mitoses per 1000 tumor cells). The median Mitotic indices among WHO grade I (n = 268), grade II (n = 84) and grade III (n = 11) tumors were 1, 4 and 12. Classification and regression tree analysis to categorize cut-offs identified three subgroups defined by Mitotic indices of 0-2, 3-4 and ≥5, which on univariate analysis were associated with RFS (P < 0.01). In multivariate analysis, Mitotic Index subgrouped in this manner was significantly associated with RFS (P < 0.01) after adjustment for Simpson grade, WHO grade and MIB-1 Index. Mitotic Index was then examined within individual WHO grade, showing that for grade I and grade II meningiomas, Mitotic Index can add additional information to RFS risk. The results suggest that the use of a robust Mitotic marker in meningioma could refine risk stratification.
-
idh mutation status and role of who grade and Mitotic Index in overall survival in grade ii iii diffuse gliomas
Acta Neuropathologica, 2015Co-Authors: Adriana Olar, Khalida Wani, Erik P Sulman, Kristin Alfaromunoz, Lindsey Heathcock, Hinke F Van Thuijl, Mark R Gilbert, Terri S Armstrong, Daniel P CahillAbstract:Diffuse gliomas are up till now graded based upon morphology. Recent findings indicate that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of tumors. The role of tumor grade and Mitotic Index in patient outcome has not been evaluated following stratification by IDH mutation status. To address this, we interrogated 558 WHO grade II–III diffuse gliomas for IDH1/2 mutations and investigated the prognostic impact of WHO grade within IDH-mutant and IDH-wild type tumor subsets independently. The prognostic impact of grade was modest in IDH-mutant [hazard ratio (HR) = 1.21, 95 % confidence interval (CI) = 0.91–1.61] compared to IDH-wild type tumors (HR = 1.74, 95 % CI = 0.95–3.16). Using a dichotomized Mitotic Index cut-off of 4/1000 tumor cells, we found that while Mitotic Index was significantly associated with outcome in IDH-wild type tumors (log-rank p < 0.0001, HR = 4.41, 95 % CI = 2.55–7.63), it was not associated with outcome in IDH-mutant tumors (log-rank p = 0.5157, HR = 1.10, 95 % CI = 0.80–1.51), and could demonstrate a statistical interaction (p < 0.0001) between IDH mutation and Mitotic Index (i.e., suggesting that the effect of Mitotic Index on patient outcome is dependent on IDH mutation status). Patient age, an established prognostic factor in diffuse glioma, was significantly associated with outcome only in the IDH-wild type subset, and consistent with prior data, 1p/19q co-deletion conferred improved outcome in the IDH-mutant cohort. These findings suggest that stratification of grade II–III gliomas into subsets defined by the presence or absence of IDH mutation leads to subgroups with distinct prognostic characteristics. Further evaluation of grading criteria and prognostic markers is warranted within IDH-mutant versus IDH-wild type diffuse grade II–III gliomas as independent entities.
D Berlato - One of the best experts on this subject based on the ideXlab platform.
-
comparison of minichromosome maintenance protein 7 ki67 and Mitotic Index in the prognosis of intermediate patnaik grade cutaneous mast cell tumours in dogs
Veterinary and Comparative Oncology, 2018Co-Authors: D Berlato, S Murphy, S Laberke, R RasottoAbstract:A previous study found that minichromosome maintenance protein 7 (MCM7) score was associated with prognosis in dogs with cutaneous mast cell tumours (MCTs) independent of histological grade. The primary aim of this study was to validate this score in a different cohort of dogs focusing exclusively on patients with Patnaik intermediate grade MCTs treated with surgery alone and followed for a minimum of 1 year. A secondary aim was to evaluate the prognostic performance of MCM7 in relation to Kiupel histological grade, Mitotic Index (MI) and Ki67 Index in the same cohort of dogs. Ninety dogs were identified, 82 were low Kiupel grade and 8 were high Kiupel grade. Seventy-two dogs were alive after a median follow-up of 1136 days and 18 dogs died of MCT-related causes after a median of 116 days. A MI threshold of 5 was associated with a sensitivity of 0.39 and a specificity of 0.99 in predicting MCT-related death; for Ki67 a threshold of 0.018 was associated with a sensitivity of 0.78 and a specificity of 0.83; and for MCM7 a threshold of 0.18 gave a sensitivity of 0.83 and a specificity of 0.86. Combining MI, Ki67 and MCM7 showed an improved accuracy of predicting death compared with each individual variable. Therefore, performing Ki67 and MCM7 in dogs with GII MCT, low Kiupel grade and low MI might be a consideration.
-
comparison of Mitotic Index and ki67 Index in the prognostication of canine cutaneous mast cell tumours
Veterinary and Comparative Oncology, 2015Co-Authors: D Berlato, S Murphy, Paola Monti, Jennifer Stewart, J R Newton, A Flindall, G MaglennonAbstract:Proliferation markers are commonly used for prognostication of mast cell tumours. The aim of the study is to compare the relative abilities of Ki67 and Mitotic Index to predict survival in the same cohort of dogs with cutaneous MCTs. Histological grade, Mitotic Index and Ki67 Index were performed in all samples and clinical information was obtained by a follow-up questionnaire. Ninety-five dogs were included in the study with a median follow-up of 1145 days. Survival times varied significantly between categories of histological grade, Mitotic Index and Ki67 Index. Multivariable analyses showed that the risk of dying due to MCT was similar in dogs with increased Ki67 Index [hazard ratio, HR: 3.0 (95% CI 1.3-6.8)] or increased Mitotic Index [HR: 2.7 (95% CI 1.1-6.5)]. In conclusion, both Mitotic Index and Ki67 Index were able to independently differentiate MCTs with worse prognosis. This distinction is particularly meaningful in selecting intermediate grade MCTs that may benefit from more aggressive local or systemic treatment.
Mark M Aloysius - One of the best experts on this subject based on the ideXlab platform.
-
predictive value of tumor proliferative indices in periampullary cancers ki 67 Mitotic activity Index mi and volume corrected Mitotic Index m v using tissue microarrays
World Journal of Surgery, 2010Co-Authors: Mark M Aloysius, Shivanthi J De Silva Hewavisenthi, Timothy E Bates, B J Rowlands, Dileep N Lobo, Abed M ZaitounAbstract:Background Morphometry [nuclear Ki-67 labelling, Mitotic activity Index (MI), and volume-corrected Mitotic Index (M/V)] for periampullary cancers using tissue microarrays has not been performed previously. The purpose of the study was to assess these indices on tissue microarray (TMA) sections constructed from patients with periampullary cancers and study their association with clinicopathological variables.
-
predictive value of tumor proliferative indices in periampullary cancers ki 67 Mitotic activity Index mi and volume corrected Mitotic Index m v using tissue microarrays
World Journal of Surgery, 2010Co-Authors: Mark M Aloysius, Shivanthi J De Silva Hewavisenthi, Timothy E Bates, B J Rowlands, Dileep N Lobo, Abed M ZaitounAbstract:Morphometry [nuclear Ki-67 labelling, Mitotic activity Index (MI), and volume-corrected Mitotic Index (M/V)] for periampullary cancers using tissue microarrays has not been performed previously. The purpose of the study was to assess these indices on tissue microarray (TMA) sections constructed from patients with periampullary cancers and study their association with clinicopathological variables. Immunohistochemical staining for Ki-67 was performed on formalin-fixed pancreatic TMA sections. Expression of Ki-67 was assessed as the percentage of cancer cell nuclei expressing MIB1, MI as the mean percentage of Ki-67 from 10 random high-power fields, and M/V was calculated after standardizing MI for connective tissue volume and microscope parameters in the tumor using established protocols. Patients ≥70 years with periampullary cancers had higher Ki-67 expression (>15) compared with patients 15) was clearly associated with worsening histological grade (χ2 = 9.2, P = 0.010). The median survival for tumors of the pancreaticobiliary subtype (pancreatic ductal adenocarcinoma and cholangiocarcinoma) was 43 months in the group with an M/V score of <20, compared with 18 months for the group with a score ≥20 (P = 0.001). There was no statistically significant difference in survival, based on M/V score, for tumors of the intestinal subtype (ampullary and duodenal adenocarcinoma). In periampullary cancers, Ki-67 and MI are proliferative indices predictive of tumor behavior. M/V was predictive of survival in tumors of the pancreaticobiliary subtype.
Daniel P Cahill - One of the best experts on this subject based on the ideXlab platform.
-
abstract 5270 idh mutation status and role of who grade and Mitotic Index in overall survival in grade ii iii diffuse gliomas
Cancer Research, 2015Co-Authors: Adriana Olar, Khalida Wani, Erik P Sulman, Lindsey Heathcock, Hinke F Van Thuijl, Mark R Gilbert, Terri S Armstrong, Daniel P Cahill, Kristin Diefes, Jaap C ReijneveldAbstract:Diffuse gliomas are up till now graded based upon morphology. Recent findings indicate that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of tumors. The role of tumor grade and Mitotic Index in patient outcome has not been evaluated following stratification by IDH mutation status. To address this, we interrogated 558 WHO grade II-III diffuse gliomas for IDH1/2 mutations and investigated the prognostic impact of WHO grade within IDH-mutant and wild-type tumor subsets independently. The prognostic impact of grade was modest in IDH-mutant [hazard ratio (HR) = 1.21, 95% confidence interval (CI) = 0.91-1.61] compared to IDH-wild type tumors (HR = 1.74, 95% CI = 0.95-3.16). Using a dichotomized Mitotic Index cut-off of 4/1000 tumor cells, we found that while Mitotic Index was significantly associated with outcome in IDH-wild type tumors (log-rank p Citation Format: Adriana Olar, Khalida Wani, Kristin Diefes, Lindsey Heathcock, Hinke van Thuijl, Mark Gilbert, Terri Armstrong, Erik Sulman, Daniel Cahill, Jaap Reijneveld, Bauke Ylstra, Pieter Wesseling, Kenneth Aldape. IDH mutation status and role of WHO grade and Mitotic Index in overall survival in grade II-III diffuse gliomas. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5270. doi:10.1158/1538-7445.AM2015-5270
-
idh mutation status and role of who grade and Mitotic Index in overall survival in grade ii iii diffuse gliomas
Acta Neuropathologica, 2015Co-Authors: Adriana Olar, Khalida Wani, Erik P Sulman, Kristin Alfaromunoz, Lindsey Heathcock, Hinke F Van Thuijl, Mark R Gilbert, Terri S Armstrong, Daniel P CahillAbstract:Diffuse gliomas are up till now graded based upon morphology. Recent findings indicate that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of tumors. The role of tumor grade and Mitotic Index in patient outcome has not been evaluated following stratification by IDH mutation status. To address this, we interrogated 558 WHO grade II–III diffuse gliomas for IDH1/2 mutations and investigated the prognostic impact of WHO grade within IDH-mutant and IDH-wild type tumor subsets independently. The prognostic impact of grade was modest in IDH-mutant [hazard ratio (HR) = 1.21, 95 % confidence interval (CI) = 0.91–1.61] compared to IDH-wild type tumors (HR = 1.74, 95 % CI = 0.95–3.16). Using a dichotomized Mitotic Index cut-off of 4/1000 tumor cells, we found that while Mitotic Index was significantly associated with outcome in IDH-wild type tumors (log-rank p < 0.0001, HR = 4.41, 95 % CI = 2.55–7.63), it was not associated with outcome in IDH-mutant tumors (log-rank p = 0.5157, HR = 1.10, 95 % CI = 0.80–1.51), and could demonstrate a statistical interaction (p < 0.0001) between IDH mutation and Mitotic Index (i.e., suggesting that the effect of Mitotic Index on patient outcome is dependent on IDH mutation status). Patient age, an established prognostic factor in diffuse glioma, was significantly associated with outcome only in the IDH-wild type subset, and consistent with prior data, 1p/19q co-deletion conferred improved outcome in the IDH-mutant cohort. These findings suggest that stratification of grade II–III gliomas into subsets defined by the presence or absence of IDH mutation leads to subgroups with distinct prognostic characteristics. Further evaluation of grading criteria and prognostic markers is warranted within IDH-mutant versus IDH-wild type diffuse grade II–III gliomas as independent entities.